Novocure News

The component stock Novavax Pharmaceuticals closed up 47.64%, continuing its 98.66% increase on Friday (May 10); AC Immune rose 42.86%, MacroGenics rose 32.33% Humacyte, Prime Medicine, Beam, Twist Bioscience, Recursion Pharmaceuticals, Coherus BioScience

The component stock Novavax Pharmaceuticals closed up 47.64%, continuing its 98.66% increase on Friday (May 10); AC Immune rose 42.86%, MacroGenics rose 32.33% Humacyte, Prime Medicine, Beam, Twist Bioscience, Recursion Pharmaceuticals, Coherus BioSciences rose 16.60%-10.00% Novocure also rose 9.17%; Zent

Zhitong FinanceMay 14 05:49

Unveiling 8 Analyst Insights On NovoCure

Throughout the last three months, 8 analysts have evaluated NovoCure (NASDAQ:NVCR), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings, shed

BenzingaMay 3 05:01

Earnings Call Summary | Novocure(NVCR.US) Q1 2024 Earnings Conference

The following is a summary of the NovoCure Limited (NVCR) Q1 2024 Earnings Call Transcript:Financial Performance:NovoCure reported a net revenue of $139 million in Q1 2024, up 13% year-over-year. The

Futu NewsMay 3 01:25 · Conference Call

Novocure Price Target Cut to $22.00/Share From $24.00 by HC Wainwright & Co.

Novocure Price Target Cut to $22.00/Share From $24.00 by HC Wainwright & Co.

Dow JonesMay 3 00:51

Novocure Is Maintained at Neutral by HC Wainwright & Co.

Novocure Is Maintained at Neutral by HC Wainwright & Co.

Dow JonesMay 3 00:51

HC Wainwright & Co. Maintains Neutral on NovoCure, Lowers Price Target to $22

HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure with a Neutral and lowers the price target from $24 to $22.

Analyst UpgradesMay 3 00:41

Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)

TipRanksMay 3 00:30

NovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported

Yahoo FinanceMay 2 20:45

Novocure Secures New $400M Non-Dilutive Debt Financing From Pharmakon

Use of proceeds to fund working capital needs stemming from Novocure's anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure's convertible notes

BenzingaMay 2 19:18

Novocure Expects Top-line Data From Phase 3 PANOVA-3 Clinical Trial in Locally Advanced Pancreatic Cancer in Q4

Novocure Expects Top-line Data From Phase 3 PANOVA-3 Clinical Trial in Locally Advanced Pancreatic Cancer in Q4

Dow JonesMay 2 19:12

NovoCure Q1 2024 Adj EPS $(0.36) Beats $(0.42) Estimate, Sales $138.50M Beat $131.45M Estimate

NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.42) by 14.29 percent. The company reported quarterly sales of $138.50 million wh

BenzingaMay 2 19:04

Earnings Flash (NVCR) NOVOCURE Reports Q1 Revenue $138.5M, Vs. Street Est of $131.5M

07:03 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (NVCR) NOVOCURE Reports Q1 Revenue $138.5M, vs. Street Est of $131.5M

MT NewswiresMay 2 19:03

Novocure 1Q Loss $38.8M >NVCR

Novocure 1Q Loss $38.8M >NVCR

Dow JonesMay 2 19:00

Novocure Price Target Raised to $28.00/Share From $25.00 by Piper Sandler

Novocure Price Target Raised to $28.00/Share From $25.00 by Piper Sandler

Dow JonesApr 10 21:05

Piper Sandler: Reiterates the NovoCure (NVCR.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $25.00 to $28.00.

Piper Sandler: Reiterates the NovoCure (NVCR.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $25.00 to $28.00.

Zhitong FinanceApr 10 21:00

Piper Sandler Reiterates Overweight on NovoCure, Raises Price Target to $28

Piper Sandler analyst Jason Bednar reiterates NovoCure with a Overweight and raises the price target from $25 to $28.

Analyst UpgradesApr 10 20:55

Is NovoCure (NASDAQ:NVCR) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much

Simply Wall StApr 9 01:49

Novocure Reports 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, At AACR Annual Meeting 2024

Novocure Reports 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, At AACR Annual Meeting 2024

BenzingaApr 5 19:01

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan

BenzingaApr 4 01:35

Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating

Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating.

MT NewswiresApr 4 00:55